cell-science-pharmacology-2017-scientifictracks

Page 27

Notes:

allied

academies

Cell Science, Stem Cell Research &

Pharmacological Regenerative Medicine

November 29-30, 2017 | Atlanta, USA

Annual Congress on

Adv cel sci tissue cul 2017 | Volume 1 Issue 2

Novel, non-toxic rifamycin that reverse drug resistance in cancers through modulation of oxidative

stress: Dual mode of action

Seyed H Mousavi-Fard, Deeann Wallis, Nian Zhou, Dwight Baker, Kimberly Loesch, Stacy Galaviz, Steve Maxwell

and

James C Sacchettini

Texas A&M University, USA

e have discovered a novel chemosensitizer (RTI-79, a

rifamycin-derivative) with a broad spectrum of action

that includes ovarian cancer and double and triple hit non-

Hodgkin’s lymphoma. RTI-79 is relatively non-toxic and has

favorable

in vivo

safety and pharmacokinetic (PK) profiles.

RTI-79 in combination therapies is effective in multiple

drug resistant cancers in mouse models. RTI-79 works by

dramatically increasing intracellular reactive oxygen species

(ROS), primarily superoxide, through redox cycling. The level

of ROS induction is directly correlated with drug sensitivity.

Importantly, RTI-79 also triggers the unfolded protein

response (UPR) that results in increased ubiquitination and

loss of Nuclear factor erythroid–related factor 2 (Nrf2),

the primary sensor for intracellular ROS. Thus, RTI-79 both

increases ROS and squelches Nrf2’s ability to respond to

ROS. This unique mechanism provides a broad and novel

approach for the very safe application of RTI-79 and other

rifamycin, in treating drug resistant cancers.

Speaker Biography

Seyed H Mousavi-Fard has a demonstrated history of working in the higher education

academia. He has advanced experimental skills in diverse fields ranging from

Diagnostics, Molecular and Cellular Biology, Genetics, Cancer Biology and Virology

area. He is a Research Professional with a PhD in Medical Sciences focused on Cancer

Biology from Texas A&M University System Health Science Center, College of Medicine.

He is effectively collaborating with several scientists with minimal supervision. He is

responsible for study protocol design and maintenance, data generation and collection,

resulting in expedited study completion and data output in undertaking projects.